Herticad

Early breast cancer w/ high levels of HER2. Monotherapy or in combination w/ paclitaxel or docetaxel as 1st treatment for metastatic breast cancer. In combination w/ aromatase inhibitors for patients w/ high levels of HER2 & hormone receptor +ve metastatic breast cancer. In combination w/ capecitabine or 5-fluorouracil & cisplatin for patients w/ metastatic gastric cancer w/ high levels of HER2.

IV infusion Dose depends on patient's body wt. Administer 1st dose over 90 min. Administer next doses over 30 min if 1st dose is well tolerated. Early breast cancer, metastatic breast cancer & metastatic gastric cancer Administer every 3 wk. Metastatic breast cancer May also be given once a wk.

Hypersensitivity to trastuzumab, murine (mouse) proteins. Severe breathing problems at rest due to cancer or if patient needs oxygen treatment.

Not for SC use. Discontinue treatment for any signs of heart failure. Monitor heart function before, during (every 3 mth) & after (up to 2-5 yr) treatment. History of heart failure, CAD, heart valve disease, high BP, taking high BP medicine; currently using doxorubicin or epirubicin; suffering from breathlessness; other treatment for cancer. Do not drive or use machines if during treatment patient experiences symptoms eg, chills or fever. Use effective contraception during treatment & for at least 7 mth after treatment. Pregnancy. Do not breastfeed during therapy & for 7 mth after last dose. Not recommended for childn & adolescents <18 yr.

Chills, fever & other flu like symptoms. Infections, diarrhea, constipation, heartburn (dyspepsia), weakness, skin rashes, chest pain, abdominal pain, joint pain, low counts of RBC & WBC, muscle pain, conjunctivitis, watery eyes, nosebleeds, runny nose, hair loss, tremor, hot flush, dizziness, nail disorders, wt loss, loss of appetite, inability to sleep (insomnia), altered taste, low platelet count, numbness or tingling of fingers & toes, redness, swelling or sores in mouth &/or throat, pain, swelling, redness or tingling of hands &/or feet, breathlessness, headache, cough, vomiting, nausea. Allergic reactions, throat infections, bladder & skin infections, shingles, breast inflammation, pancreas or liver inflammation, kidney disorders, increased muscle tone or tension (hypertonia), arm &/or leg pain, itchy rash, sleepiness (somnolence), bruising, hemorrhoids, itchiness, dry mouth & skin, dry eyes, sweating, feeling weak & unwell, anxiety, depression, abnormal thinking, asthma, lung infection/disorders, back, neck & bone pain, acne, leg cramps.

May increase cardiotoxicity of antineoplastic agents. May increase neutropenic effect of immunosuppressants. May increase serum level w/ paclitaxel.

Targeted Cancer Therapy

L01FD01 - trastuzumab ; Belongs to the class of HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors. Used in the treatment of cancer.

Rx